It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Mass spectrometry-based methods can provide a global expression profile and structural readout of proteins in complex systems. Preserving the in vivo conformation of proteins in their innate state is challenging during proteomic experiments. Here, we introduce a whole animal in vivo protein footprinting method using perfusion of reagents to add dimethyl labels to exposed lysine residues on intact proteins which provides information about protein conformation. When this approach is used to measure dynamic structural changes during Alzheimer’s disease (AD) progression in a mouse model, we detect 433 proteins that undergo structural changes attributed to AD, independent of aging, across 7 tissues. We identify structural changes of co-expressed proteins and link the communities of these proteins to their biological functions. Our findings show that structural alterations of proteins precede changes in expression, thereby demonstrating the value of in vivo protein conformation measurement. Our method represents a strategy for untangling mechanisms of proteostasis dysfunction caused by protein misfolding. In vivo whole-animal footprinting should have broad applicability for discovering conformational changes in systemic diseases and for the design of therapeutic interventions.
This study introduces an in vivo protein footprinting method, revealing structural changes in proteome during progressing AD. It demonstrates these changes occur before expression alterations, advancing understanding of protein misfolding mechanisms.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 La Jolla, Department of Molecular Medicine, The Scripps Research Institute, California, USA (GRID:grid.214007.0) (ISNI:0000 0001 2219 9231)
2 La Jolla, Department of Molecular Medicine, The Scripps Research Institute, California, USA (GRID:grid.214007.0) (ISNI:0000 0001 2219 9231); Yuseong-gu, Department of Convergent Bioscience and Informatics, Chungnam National University, 99 Daehak-ro, Daejeon, Republic of Korea (GRID:grid.254230.2) (ISNI:0000 0001 0722 6377)
3 La Jolla, Department of Molecular Medicine, The Scripps Research Institute, California, USA (GRID:grid.214007.0) (ISNI:0000 0001 2219 9231); The Scripps Research Institute, Neurodegeneration New Medicines Center, La Jolla, USA (GRID:grid.214007.0) (ISNI:0000 0001 2219 9231); San Diego, Department of Neurosciences School of Medicine University of California, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)